JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 10 No. 1 18-27
© 1969 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Mara, R. E.
Right arrow Articles by Burger, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Mara, R. E.
Right arrow Articles by Burger, C. L.

Comparison of 113mIn and Other Short-Lived Agents for Cerebral Scanning

Robert E. O'Mara, G. Subramanian, John G. McAfee and Charles L. Burger

State University of New York, Upstate Medical Center, Syracuse, New York

Correspondence: For reprints contact: Robert E. O'Mara, Div. of Nuclear Medicine and Radiobiology, Upstate Medical Center, State University of New York, Syracuse, N.Y., 13210.

ABSTRACT

113mIn-DTPA is a satisfactory short-lived agent for brain-imaging applications. The degree of accuracy in the diagnosis of cerebral lesions in this small clinical series was comparable to 99mTc-pertechnetate. 113mIn-DTPA appeared to offer certain advantages over the latter agent including: (1) more rapid clearance from the bloodstream; (2) superior tumor-to-brain concentration ratios in both transplanted ependymoblastomas in mice and in human tumors; (3) absence of visible concentration in the choroid plexus and salivary glands; and (4) more economy for continuous use because of the much longer physical half-life of the parent nuclide 113Sn. Thus in remote geographical areas one may be relieved of the dependence on weekly shipments of a generator system.

These features, however, are offset by certain characteristics which are inferior to those of 99mTc: (1) the higher energy of the gamma emission tends to produce somewhat inferior images to 99mTc in resolution and, because collimators with thicker septa must be used, the sensitivity of detection of 113mIn is lower for the same activity of 99mTc; (2) the fraction of gamma emission undergoing internal conversion is higher than for 99mTc, and this contributes to the radiation dose; (3) the radiation dose to the "critical organ," the bladder, is higher than for 99mTc; (4) the agent is not as satisfactory as 99mTc for imaging studies with the Anger camera because of somewhat poorer resolution and fall-off in detector efficiency with the higher gamma energy; and (5) repeat studies cannot be performed in the face of unsatisfactory examinations because of the rapid blood and tissue clearance combined with a relatively short physical half-life.

Compared with 68Ga, the only other radioactive cation available from a generator system, 113mIn appears to be much superior for imaging applications except for coincidence counting systems. Furthermore, the radiation dose levels are much lower than for equivalent activities of 68Ga.

As a radioactive cation 113mIn may find important applications in the future in various compounds which cannot be labeled with anionic 99mTc.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1969 by the Society of Nuclear Medicine.